Focus on Optimized Dosing of Ibrutinib Panel Discussion

First International Summit on Interventional Pharmacoeconomics

Blase Polite, MD, MPP, FASCO, on Transforming the Drug Cost Curve in the United States: Not How But If

R. Donald Harvey, PharmD, BCOP, FCCP, FHOPA, on Cutting Cancer Care Costs With Alternative Pharmacologic Options

R. Donald Harvey, PharmD, BCOP, FCCP, FHOPA, of Emory University, discusses the ways in which clinical pharmacology can help yield cost savings without sacrificing efficacy by, for example, altering regimens to extend drug supplies, lowering doses, dosing less frequently, or shortening the duration of treatment.

Cody Peer, PhD, on Simulating Alternative Schedules for Checkpoint Inhibitors

Varsha Gandhi, PhD, on Ibrutinib

Leonard B. Saltz, MD, on the Future of Interventional Pharmacoeconomics

Nov

Today In Oncology

Focus on Optimized Dosing of Ibrutinib Panel Discussion

Related Videos

Blase Polite, MD, MPP, FASCO, on Transforming the Drug Cost Curve in the United States: Not How But If

R. Donald Harvey, PharmD, BCOP, FCCP, FHOPA, on Cutting Cancer Care Costs With Alternative Pharmacologic Options

Cody Peer, PhD, on Simulating Alternative Schedules for Checkpoint Inhibitors

Varsha Gandhi, PhD, on Ibrutinib

Leonard B. Saltz, MD, on the Future of Interventional Pharmacoeconomics

Newly Diagnosed AL Amyloidosis FDA Grants Traditional Approval to Regimen

New Computational Tool Shows Strong Accuracy in Predicting Cancer Drug Targets

Curative Treatment After First-Line Immunotherapy Improves Survival in HCC

Long-Term Survival With vs Without Postmastectomy Chest Wall Irradiation in Breast Cancer

FDA Approves Selumetinib for Adults With NF1 With Symptomatic, Inoperable Plexiform Neurofibromas